Content :

2 O Methyltransferase is a highly efficient recombinant enzyme specifically designed to catalyze the methylation modification of RNA molecules at the 2 oxygen position of specific nucleotides. In the preparation of mRNA vaccines and therapeutic RNA, it serves as a core tool enzyme for achieving precise and efficient co-transcriptional capping (Cap 1 structure formation), ensuring that RNA products meet high-end application standards for stability, translation efficiency, and immunogenicity.
The mRNA Cap 2 O Methyltransferase catalyzes the addition of a methyl group to the 2 O position of the first nucleotide adjacent to the 5 cap structure of RNA. This enzyme uses S adenosylmethionine (SAM) as the methyl donor to convert Cap 0 to Cap 1.
The enzyme specifically recognizes RNA with an m7GpppN cap structure. It cannot catalyze RNA with 5 ends containing pN, ppN, pppN, or GpppN. Capped RNA can be prepared either by in vitro transcription using cap analogs or by enzymatic capping using Vaccinia Virus Capping Enzyme.

Applicable Scenarios:
mRNA in vitro transcription (IVT) synthesis, therapeutic RNA process development and production, basic research on RNA structure, function, and modification mechanisms
Product Advantages:
Stable performance, easy operation, suitable for high throughput modification reactions.2 O methyltransferase, through RNA methylation modification, has significant advantages in enhancing RNA stability, regulating gene expression, antiviral defense, and diversifying RNA functions, and has shown broad application potential in biotechnology.
Precise capping modification: Catalytic RNA specific 2 O site methylation, forming standard Cap1 structure
Low background interference: Precise modification, background activity extremely low, avoiding interference at non target sites
Excellent compatibility: Perfectly compatible as the core component of capping with common in vitro transcription systems